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POSTOPERATIVE ANALGESIA IN CHILDREN: AN 
UPDATE
Gurmukh Das Punshi*, mohammaD hamiD**
anD mansour ahmeD khan***
Introduction
Acute pain is one of the most common adverse stimuli experienced by pediatric population 
as a result of surgery, illness, any injury and necessary medical procedure. Pain is associated with 
increased anxiety, avoidance, somatic symptoms, and increased parent distress and may lead to 
long term effects1.
Despite the magnitude of these effects, the acute pain has on a child is often inadequately 
assessed and treated. Numerous myths, insufficient knowledge among caregivers, and inadequate 
application of knowledge contribute to the lack of effective management2. Fear of adverse reactions 
and toxic effects often contributed to the inadequate use of analgesics.
The International Association for the Study of Pain has defined pain as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage or described in terms 
of such damage3. Several experts suggest that the neonate’s expression of pain does not fit within 
the strict definition of the International Association for Study of Pain because of the requirement 
for self-report. This lack of ability to report pain contributes to the failure to recognize and treat 
pain aggressively during infancy and early childhood3. Because neonates cannot verbalize their 
pain, they depend on others to recognize, assess, and manage their pain. Therefore, health care 
professionals can diagnose neonatal pain only by recognizing the neonate’s associated behavioral 
and physiological responses.
A large scale survey reported that 40% of pediatric surgical patients experienced moderate 
or severe postoperative pain and that 75% had insufficient analgesia4. The structural components 
necessary to perceive pain are already present at about 25 weeks gestation whereas the endogenous 
descending inhibitory pathways are not fully developed until mid-infancy5. Opioid and other 
receptors are much more widely distributed in fetuses and neonates6. Fetuses subjected to intrauterine 
exchange transfusion with needle trans-hepatic access will show both behavioral signs of pain as 
well as a hormonal stress response7. Significant pain stimulation without proper analgesia, for 
example during circumcision, will not only cause unacceptable pain at the time of the intervention 
but also produces a ‘pain memory’ as illustrated by an exaggerated pain response to vaccination 
as long as six months following the circumcision8. Both neonates and infants are able to mount 
a graded hormonal stress response to surgical intervention and adequate intra- and postoperative 
analgesia will not only modify the stress response but has also been shown to reduce morbidity 
and mortality9-10.
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The following guidelines are designed to support 
quality health care and effective management of acute 
intraoperative and postoperative pain management. 
Objective of present guidelines are to recognize pain 
in children, minimize moderate and severe pain safely 
in all children, prevent pain if possible, bring pain 
rapidly under control and to continue pain control after 
discharge from the hospital.
Assessment Tools
Recognition and assessment of pain is the first and 
most important step in successful pain management. 
Pain should be assessed on a regular basis using 
self-report, behavioral observation and physiologic 
measures, bearing in mind the age of the child and his 
or her communication capabilities. There are many 
different scales that can be used in different age groups. 
It is of importance to use a scale that is feasible in the 
clinical setting11.
= Children eight year of age and above can generally 
use visual analogue pain scales used by adults, 
which involve rating the intensity of pain on a 
horizontal scale.
1. -------------------------------------------------------10
= For children from three to eight years old, self 
reported measures use either face scales (series 
of photographs or drawings of faces showing 
increasing degree of distress) or color-analogue 
scales (rulers with increasing intensity of red 
color signifying increasing intensity of pain). 
Good agreement was reported between the results 
obtained with a photographic face scale and those 
obtained with a color-analogue scale among three 
to seven year old children12.
= Behavioral observational scales are the primary 
methods of pain assessment for neonates, infants, 
and children under four years of age or for 
children with developmental disabilities12. Such 
scales may score facial expressions, limb and 
trunk motor responses, verbal responses, crying 
or combinations of behavioral and autonomic 
measures. Some of these scales record “distress”, 
which reflects fear and anxiety as well as pain. 
Behavioral scales may under represent the 
intensity of persistent pain, as compared with 
self-reports.
= Physiological indexes of pain are useful and 
include changes in heart rate, respiratory 
rate, blood pressure, oxygen saturation, vagal 
tone, palmer sweating, and plasma cortisol or 
catecholamine concentrations although they may 
be nonspecific. For example, tachycardia may 
be caused by hypovolemia or hypoxemia, rather 
than pain. Thus, pain assessment in neonates, 
infants, and children less than four years of age 
and in children with major disabilities remains a 
challenge.
Techniques of Pain Control
Combination of pharmacological and non 
pharmacological techniques have proven to be useful 
in managing pain in children.
Non pharmacological
A variety of non pharmacologic pain prevention 
and relief techniques have been shown to effectively 
reduce pain from minor procedures in neonates. These 
include use of oral sucrose/glucose, breastfeeding, 
nonnutritive sucking, “kangaroo care” (skin-to-skin 
contact), facilitated tuck (holding the arms and legs 
in a flexed position), swaddling, and developmental 
care, which include limiting environmental stimuli, 
lateral positioning, the use of supportive bedding and 
physical therapy. These measures have been shown 
to be useful in preterm and term neonates in reducing 
pain from a heel stick, venipuncture, and subcutaneous 
injections and are generally more effective when used 
in combination13.
Pharmacological
Analgesics can be administered through different 
routes depending on the age, type of procedure, 
presence of intravenous line, patient preference and 
severity of pain.
Oral route
Oral route is the preferred approach in routine 
practice. Alternative routes are necessary for patients 
who have impaired swallowing or gastrointestinal 
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Rectal route
Rectal route is particularly useful in immediate 
postoperative period where patient is not allowed to 
take oral medication.
Regional (Table 1)
Regional analgesia includes Local infiltration, 
Peripheral nerve blocks and Central nerve blocks 
(spinal, epidural, Caudal). The most common regional 
block in pediatric patient is caudal block.
Non Steroidal Anti Inflammatory Drugs 
 (Table 2)
There are mainly four categories of drugs which 
are effective in pain management. These are non 
opioids (Paracetamol, Non steroidal anti-inflammatory 
drugs, and clonidine), opioids (Morphine, Meperidine, 
and Tramadol), local anesthetics and adjuvant drugs.
dysfunction, those who require a very rapid onset of 
analgesia and those who are unable to utilize or tolerate 
the oral route.
Intravenous route
Analgesics are administered as single or 
intermittent boluses or as a continuous infusion. For 
prolonged use, continuous infusion is preferred to 
avoid large variations in plasma concentration. The 
safety and efficacy of patient-controlled analgesia for 
children as young as six years is supported by controlled 
trials12. Nurse-activated patient-controlled analgesia is 
now widely used for infants9 as a convenient way to 
prevent delays in relieving episodic pain.
Activation of the button for patient-controlled 
analgesia by parents (parent-controlled analgesia) is 
widely accepted in palliative care. However, its use 
for postoperative pain is controversial because of 
the potential for either overdosing or under dosing, 
subjects who have not received opioids before.
Table 1 
Maximum local anesthetic doses in infants and children
Drugs Dose mg/kg Continuous epidural analgesia (CEA) mg/ml
Lidocaine (plain) 5 Not available
Lidocaine (epinephrine) 7 Not available
Bupivacaine 2: < 3 months
3: child dose
1 (0.5-1.25)
Levobupivacaine 2 Not available
Ropivacaine 2 1 (0.5-1.25)
Table 2 
Recommended doses of non-steroidals for pediatric patients4,11,14,15
Drugs Dose Interval (hours) Maximum daily dose
Acetaminophen 5-15 mg/kg PO 4-6 Children:< 100mg/kg/day
Infants: 75mg/kg/day
Newborns:
(< 32 wks PCA):60 mg/kg/d
(28–32 wks PCA): 40 mg/kg/d
Ibuprofen 4-10 mg/kg PO 6 < 40mg/kg/day
Naproxen 5-10 mg/kg PO 8-12 20 mg/kg/day
Diclofenac 1-2 mg/kg PO 8-12 Not available
Ketorolac 0.3-0.5 mg/kg I/V 6-8 < 2mg/kg/day
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which in turn sensitize peripheral nerve endings 
and vasodilate vessels, causing pain, erythema, and 
inflammation. There are two COX isoenzymes. 
The constitutive form of COX (COX-1) is present 
throughout the body and the prostaglandins and 
thromboxanes that are produced are essential for 
functions such as gastric mucosa protection, renal 
blood flow regulation, and platelet aggregation. 
Potential complications of COX-1 inhibition include 
gastric ulceration, bleeding, altered renal function, and 
bronchoconstriction. COX-2 is called an ‘‘inducible 
COX’’ and is present only in traumatized cells or 
inflamed tissue. Most NSAIDs are nonselective COX 
inhibitors, but the potential attraction of selective 
COX-2 inhibition in the reduction of side effects is 
apparent. Presently, the future of COX-2 inhibitors in 
children is uncertain14. Ibuprofen can be administered 
6-8 hours interval in doses of 8mg/kg PO and 20mg/
kg rectally15. Ketorolac in doses of 0.4 to 1.0 mg/kg 
is useful for mild to moderate pain in children when 
parenteral administration is required15.
OPOIDS (Tables 3, 4, 5)
Opioids are morphine like substances. The term 
opoid is derived from opium (from the Greek term 
for juice) which is extracted from the poppy plant. 
Opioids are used for moderate to severe nociceptive 
pain. Opioids bind to pre- and postsynaptic cell 
membranes in the central nervous system through 
the specific opioid receptors, resulting in neuronal 
inhibition by decreasing excitatory neurotransmitter 
release from presynaptic terminals or by 
hyperpolarizing the postsynaptic neuron. Opioid 
receptors are classified as mu, kappa, delta, and sigma. 
The mu receptor is further subdivided into subclasses 
mu1, which mediates supraspinal analgesia and 
dependence, and mu 2, which mediates respiratory 
depression, intestinal dysmotility, sedation, and 
bradycardia. Opioids are classified as agonists, 
partial agonists, agonist-antagonists, and antagonists. 
Examples of the mu1 agonists include morphine, 
hydromorphone, meperidine, methadone, fentanyl, 
sufentanil, remifentanil, codeine, oxycodone, and 
hydrocodone.
Acetaminophen (Paracetamol)
Acetaminophen is the most widely prescribed 
analgesic used for mild type of all pains. It lacks the 
troublesome side effects of other NSAIDs. Its effects 
are mediated by central cyclooxygenase III (COX-
III) inhibition. Acetaminophen can be given orally or 
rectally. Acetaminophen is metabolized in the liver 
primarily by glucuronidation and sulfation14.
The recommended oral dosage is 10 to 15 mg 
per kilogram every four hours for children15. Rectal 
administration produces delayed and variable uptake; 
single bolus dose of 35 to 45 mg per kilogram generally 
produces therapeutic plasma concentrations, with 
prolonged clearance. Subsequent rectal doses should 
be smaller (e.g., 20mg per kilogram), and the interval 
between doses should be extended to at least six to 
eight hours.
Single rectal doses of 20 mg per kilogram 
produced safe plasma concentrations in preterm 
neonates. Daily cumulative acetaminophen doses by 
the oral or rectal route should not exceed 100 mg per 
kilogram per day for children, 75 mg per kilogram 
for infants, 60 mg per kilogram for term and preterm 
neonates beyond 32 weeks of postconceptional age, 
and 40 mg per kilogram for preterm neonates from 28 
to 32 weeks of postconceptional age12.
Acetylsalicylic acid (Aspirin)
Because of its association with Reye’s syndrome, 
aspirin is now used only rarely in pediatric patients 
suffering from rheumatologic conditions14 can be 
prescribed as 10-15mg/kg PO4.
NSAIDs
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are used for the management of mild to 
moderate pain. They are used alone or in combination 
with opioids. Main advantage of NSAIDs is lack of 
respiratory depression and sedation. Their mechanism 
of action is through the inhibition of cyclooxygenase 
(COX), the enzyme responsible for metabolizing 
arachidonic acid. When arachidonic acid is released 
from traumatized cell membranes, it is metabolized 
by COX to form prostaglandins and thromboxanes, 
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Morphine
Morphine is the standard opioid with which 
all other opioids are compared16. It has a rather poor 
oral bioavailability (25-40%), which necessitates a 
larger oral dose when converting from i.v. to enteral 
administration11. It can be given through multiple 
routes (intravenous, oral, subcutaneous, intrathecal, 
epidural, and intra-articular). Morphine is metabolized 
in the liver to morphine-3-glucuronide (inactive) and 
morphine-6-glucuronide (active), which are both 
excreted by the kidneys. Generally, the elimination 
half-life is longer and the clearance is decreased in 
newborns compared with older children and adults. 
This difference is especially pronounced in preterm 
neonates. In addition, less morphine is protein bound 
in neonates, allowing a greater proportion of unbound 
Agonist-antagonist opioids, which are agonists at 
one receptor type and antagonists at another receptor, 
include nalbuphine and pentazocine. Analgesia 
by agonist-antagonists is mainly kappa & sigma-
mediated, with antagonism or partial agonism at the 
mu receptor.
A partial agonist such as buprenorphone exerts 
less than full response at a receptor site.
Opioid antagonists include naloxone and naltrexone.
Side-effects common to opioid agonists include 
respiratory depression, sedation, nausea, vomiting, 
pruritus, urinary retention, ileus, and constipation. 
Less common effects are dysphoria, hallucinations, 
seizures, and myoclonic movements. Opioids can be 
used as oral, sublingual, transdermal, intranasal, and 
rectal routes3.
Table 4 
Recommended continuous infusion dose of opioids for pediatric patients4,11,15
Drugs Continuous infusion rate doses
Meperidine 0.1 0.3 mg/kg/hr
Morphine 10-40 mcg/kg/hr
Fentanyl 0.5 mcg/kg/hr
Nalbuphine 10-15 mcg/kg/hr
Table 5 
Recommended PCIA dose of opioids for pediatric patients
Drugs Bolus dose mcg/kg Lockout interval min Continuous infusion mcg/kg/hr 1 hour limit mcg/kg/hr
Morphine 20 8-10 0-20 100
Fentanyl 0.5 6-8 0-0.5 25
Nalbuphine 20 8-10 0-20 100
Table 3 
Recommended single doses of opioids for pediatric patients4,11,14,15
Drugs Single dose Interval (hours) Potency (relative to morphine)
Codeine 0.5-1 mg/kg PO 4-6 Not available
Meperidine 0.5-1.0 mg/kg I/V 2-3 0.1
Morphine 0.05-0.15mg/kg I/V 0.3mg/kg 
PO
2
3-4
1
Fentanyl 0.5-1 mcg/kg I/V 1-2 50-100
Tramadol 1-2 mg/kg I/V 0.1
Nalbuphine 25-50 mcg/kg I/V 2-4
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duration of action.
Transmucosal fentanyl permits rapid onset of 
analgesia for brief, painful procedures in hospitalized 
children in whom intravenous access is not available. 
Transmucosal is more efficient than oral administration 
because it bypasses the hepatic first pass metabolism 
of the oral route, which reduces the availability of 
fentanyl by 25% to 33%14.
Transdermal fentanyl provides a consistent 
analgesic effect for selected patients, such as children 
with severe pain due to cancer. Transdermal fentanyl 
administration is available in patches of 25, 50, 75, and 
100 mg/h for use lasting 2 to 3 days. It has a long onset 
time but also a long duration that persists after the patch 
is removed14. Fentanyl can be given intravenously as a 
single bolus of 1-1.5 µg/kg or infuse continuously at 
2-4 µg/kg/hr15.
Codeine
Codeine is used to treat moderate pain11. Codeine 
is a mu agonist and a derivative of morphine. It is a 
commonly used oral opioid most often combined with 
acetaminophen in liquid or tablet form. Codeine is 
0.10 times as potent as morphine. Its bioavailability 
is 60% after oral administration, with an onset time 
of 20 minutes and an elimination half-life of 2.5 to 
3 hours. Codeine is metabolized in the liver and then 
excreted in the urine18. Five to ten percent of codeine is 
metabolized by O-demethylation in the liver by a P-450 
oxidase pathway (CYP2D6) to produce morphine. 
This conversion is necessary for analgesia to occur 
after codeine administration. When the codeine and 
acetaminophen combination is used, care must be taken 
to stay within safe dosage ranges of acetaminophen14. 
Recommended doses: 0.5-1 mg/kg PO with 4-6 hr 
interval15.
Nalbuphine
Nalbuphine is a kappa agonist and a mu antagonist. 
It has an analgesia equivalent to morphine up to a dose 
of approximately 200 mg/kg, at which point it has a 
ceiling effect of analgesia. Kappa mediated side effects 
of sedation, dysphoria, or euphoria are likely at higher 
doses. Nalbuphine is metabolized mainly in the liver 
and has a half-life of approximately 5 hours. It is 
usually given intravenously. When given orally, it has 
morphine to penetrate the brain, thus increasing the 
risk for respiratory depression. The elimination half-
life and clearance reach adult values within 2 months 
of age16.
Recommended single intravenous dose is 0.08-0.1 
mg/kg while epidural and caudal are given as 50 mcg/
kg and 120-150 mcg/kg respectively15. If morphine 
is given by PCA, start with bolus dose of 20 mcg/kg, 
lockout interval 5 min with or without background 
infusion 4 mcg/kg/h (especially first 24 h)4.
Pethidine (Meperidine)
Meperidine is a synthetic opioid derived from 
phenylpiperidine. It has 1/10th the analgesic potency of 
morphine and is metabolized in the liver by hydrolysis 
and N-demethylation. It has an elimination half-life 
of approximately three hours. It offers no advantage 
over morphine in terms of side effects. The primary 
metabolite, normeperidine, can cause hallucinations, 
agitation and seizures, when meperidine is used for 
an extended period11. It can be used intramuscularly & 
intravenously. It is used in single doses for postoperative 
shivering17 Meperidine should also not be used in 
conjunction with monoamine oxidase inhibitors or in 
patients with hyperthyroidism14.
Recommended intravenous dose is 1-1.5 mg/
kg with 2-3 hour interval after titration while usual 
intramuscular dose is 0.8-1 mg/kg with 3-4 hour 
interval15.
Fentanyl
Fentanyl is a synthetic opioid that is 100 times 
more potent than morphine. It is highly lipophilic, 
resulting in significant brain penetration. Fentanyl has a 
short duration of action because of redistribution out of 
the plasma into body tissues14. Metabolism is through 
glucuronidation in the liver to inactive metabolites that 
are excreted by the kidney. Because of its potency, 
hemodynamic stability, and brief duration of action 
in small doses, fentanyl is an attractive analgesic 
for short painful procedures in children, especially 
in an intensive care unit setting16. Fentanyl can be 
given through multiple routes: intravenous, epidural, 
intrathecal, nasal, transmucosal, and transdermal. With 
repeated dosing or with prolonged infusions, fentanyl 
may accumulate in the body and leads to longer 
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procedures in children in the emergency room and ICU 
settings. It can be administered intravenously, orally, 
rectally, and intramuscularly14. In the postoperative 
period a low-dose continuous infusion can offer 
an improved pain situation while minimizing side 
effects. Because of increased secretions and possible 
dysphoric effects, ketamine is often combined with 
an anticholinergic agent and a benzodiazepine. The 
analgesic effects of ketamine are mediated by NMDA 
receptor antagonism. Oral bioavailability is 20% to 
25%. Ketamine is highly lipid soluble, with rapid 
redistribution. Ketamine is N-demethylated in the liver 
by the cytochrome P-450 system Intravenous doses of 
0.25 to 0.5 mg/kg can produce intense analgesia for 10 
to 15 minutes, although the elimination half-life is 2 to 
3 hours. A dose of 1 to 2 mg/kg IV may be needed for 
more painful procedures such as fracture reduction.
Conclusion
Despite several advances in assessment and 
management of acute pediatric pain, significant number 
of children still suffer from moderate to severe pain in 
the postoperative period. There is a need for education 
and training of care provider, evidence based research, 
development of easily applicable assessment tool 
and effective treatment of pain by pharmacological 
and non pharmacological means. Institutions should 
develop and implement guidelines and protocols for 
pediatric pain prevention, assessment and management 
according to local environment.
a bioavailability of only 20% to 25%. Care is needed 
when using nalbuphine in opioid-dependent children 
in order not to induce opioid withdrawal14.
Naloxon
Naloxone is antagonist at all opioid receptors. It 
is used for opioid induced side effects, like respiratory 
depression. It also is used in smaller doses for pruritis 
(1-2 mcg/kg IV). Naloxone is metabolized in the liver 
and has an elimination half-life of 60 minutes14.
Tramadol
Tramadol a synthetic cyclohexanol, 4-phenyl-
pipridine chiral racemic analog of codeine, is a 
centrally acting analgesic that possesses weak affinity 
for the mu opoid receptor and modifies transmission 
of nociceptives impulses through inhibition of 
monoamines (norepinephrine and serotonin) reuptake, 
but not production. Tramadol is approximately 1/10 as 
potent an analgesic as morphine15. In general, tramadol 
is a safe and effective analgesic for mild to moderate 
pain in children19. The recommended dose of tramadol 
is 1 to 2 mg/kg (maximum 100 mg) every 6 hours, with 
a maximum daily dose of 8 mg/kg/d or 400 mg/d14.
Ketamine
Ketamine is a phencyclidine derivative and 
a dissociative anesthetic. It is a potent analgesic in 
subanesthetic doses and is often used for short painful 
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